About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
US EPA Evaluation of Endocrine Disrupting Chemicals (EDCs)
By
Jennifer Sass
626 views
October 9, 2023
1 Comment
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Related Content
AUTOPLAY
ON
47:11
Houston Methodist Hospital
The Protein Myth: Our Obsession With Protein and How It Is Killing US
Feat.
G. Davis
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
11:28
Insights from 2023 SABCS
SABCS 2023 Insights: "ctDNA Monitoring of ER+/HER2- High Risk B…
Feat.
L. Pusztai
49:07
SABCS 2022 Conference Coverage
SABCS 2022 Expert Panel Discussion: Practice-Changing Updates
Feat.
J. O'Shaughnessy,
S. Tolaney,
S. Hurvitz,
H. Rugo
50:59
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Panel Discussion: "Early Stage Breast Cancer"
Feat.
S. Tolaney,
H. Rugo
23:58
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "mBC Expert Panel Discussion on Key Trials …
Feat.
H. Rugo,
K. Jhaveri
21:37
Dana-Farber Cancer Institute
Standard Treatments for HR+/HER2- mBC in 2023
Feat.
S. Sammons
53:42
PleXus Communications
Managing Women's Health in Menopause: Evolving Approaches for t…
Feat.
J. Simon,
T. Iyer,
A. Fiffick,
M. Minkin
18:49
Yale School of Medicine
Menopause and Hot Flashes: What Medications are Available?
Feat.
M. Minkin
29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Optimal Duration of Endocrine Therapy for Breast Cancer
Feat.
V. Kaklamani
09:41
Insights from 2023 SABCS
SABCS 2023 Insights: "ADAPTcycle Trial - Impact of Age and Ovar…
Feat.
O. Gluz
03:05
ecancer
ASCO® 2023 Insights: "Phase III NATALEE Trial - Ribociclib + ET…
Feat.
D. Slamon
07:34
PrecisCa
Summary of the Updated Results of SOFT/TEXT Trials and the Meta-Anal…
Feat.
M. Pegram
13:32
13th Annual Winter Breast Cancer Symposium
2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs
Feat.
W. Gradishar
08:48
James Martin
2L Therapy for ER+ mBC Following CDK4/6i
03:04
Insights from 2023 SABCS
SABCS 2023 Insights: "The Future of Oral SERDs in Breast Cancer…
Feat.
E. Hamilton
08:54
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…
Feat.
S. Tolaney,
H. Rugo
